Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where B. García-Muñoz is active.

Publication


Featured researches published by B. García-Muñoz.


Alimentary Pharmacology & Therapeutics | 2015

Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids

M. Robles-Díaz; A. González-Jiménez; I. Medina-Cáliz; Camilla Stephens; Miren García-Cortés; B. García-Muñoz; A. Ortega-Alonso; Encarnación Blanco-Reina; R. Gonzalez‐Grande; M. Jimenez‐Perez; P. Rendón; J. M. Navarro; Pere Ginès; M. Prieto; M. Garcia‐Eliz; Fernando Bessone; J. R. Brahm; R. Paraná; M.I. Lucena; R.J. Andrade

We have observed an increase in hepatotoxicity (DILI) reporting related to the use of anabolic androgenic steroids (AAS) for bodybuilding.


Journal of Hepatology | 2016

Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury

I. Medina-Cáliz; M. Robles-Díaz; B. García-Muñoz; Camilla Stephens; A. Ortega-Alonso; Miren García-Cortés; A. González-Jiménez; J. Sanabria-Cabrera; Inmaculada Moreno; M. Carmen Fernández; Manuel Romero-Gómez; J.M. Navarro; Ana Mª Barriocanal; Eva Montane; H. Hallal; S. Blanco; Germán Soriano; Eva Román; Elena Gómez-Dominguez; A. Castiella; Eva Zapata; Miguel Jimenez-Perez; J.M Moreno; Ana Aldea-Perona; Manuel Hernández-Guerra; Martín Prieto; M.E. Zoubek; Neil Kaplowitz; M. Isabel Lucena; Raúl J. Andrade

BACKGROUND & AIMS Chronic outcome following acute idiosyncratic drug-induced liver injury (DILI) is not yet defined. This prospective, long-term follow-up study aimed to analyze time to liver enzyme resolutions to establish the best definition and risk factors of DILI chronicity. METHODS 298 out of 850 patients in the Spanish DILI registry with no pre-existing disease affecting the liver and follow-up to resolution or ⩾1year were analyzed. Chronicity was defined as abnormal liver biochemistry, imaging test or histology one year after DILI recognition. RESULTS Out of 298 patients enrolled 273 (92%) resolved ⩽1year from DILI recognition and 25 patients (8%) were chronic. Independent risk factors for chronicity were older age [OR: 1.06, p=0.011], dyslipidemia [OR: 4.26, p=0.04] and severe DILI [OR: 14.22, p=0.005]. Alanine aminotransferase (ALT), alkaline phosphatase (ALP) and total bilirubin (TB) median values were higher in the chronic group during follow-up. Values of ALP and TB >1.1 x upper limit of normal (xULN) and 2.8 xULN respectively, in the second month from DILI onset, were found to predict chronic DILI (p<0.001). Main drug classes involved in chronicity were statins (24%) and anti-infectives (24%). Histological examination in chronic patients demonstrated two cases with ductal lesion and seven with cirrhosis. CONCLUSIONS One year is the best cut-off point to define chronic DILI or prolonged recovery, with risk factors being older age, dyslipidemia and severity of the acute episode. Statins are distinctly related to chronicity. ALP and TB values in the second month could help predict chronicity or very prolonged recovery. LAY SUMMARY Drug-induced liver injury (DILI) patients who do not resolve their liver damage during the first year should be considered chronic DILI patients. Risk factors for DILI chronicity are older age, dyslipidemia and severity of the acute episode. Chronic DILI is not a very common condition; normally featuring mild liver profile abnormalities and not being an important clinical problem, with the exception of a small number of cases of early onset cirrhosis.


Clinical Gastroenterology and Hepatology | 2018

Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry

I. Medina-Cáliz; Miren García-Cortés; A. González-Jiménez; M. Cabello; M. Robles-Díaz; J. Sanabria-Cabrera; Rocio Sanjuan-Jimenez; A. Ortega-Alonso; B. García-Muñoz; Inmaculada Moreno; Miguel Jimenez-Perez; M. Carmen Fernández; Pere Ginès; Martín Prieto; Isabel Conde; H. Hallal; Germán Soriano; Eva Román; A. Castiella; Encarnación Blanco-Reina; Maria R. Montes; Marta Quiros-Cano; Flores Martín-Reyes; M. Isabel Lucena; Raúl J. Andrade

Background & Aims There have been increasing reports of liver injury associated with use of herbal and dietary supplements, likely due to easy access to these products and beliefs among consumers that they are safer or more effective than conventional medications. We aimed to evaluate clinical features and outcomes of patients with herbal and dietary supplement‐induced liver injuries included in the Spanish DILI Registry. Methods We collected and analyzed data on demographic and clinical features, along with biochemical parameters, of 32 patients with herbal and dietary supplement‐associated liver injury reported to the Spanish DILI registry from 1994 through 2016. We used analysis of variance to compare these data with those from cases of liver injury induced by conventional drugs or anabolic androgenic steroid‐containing products. Results Herbal and dietary supplements were responsible for 4% (32 cases) of the 856 DILI cases in the registry; 20 cases of DILI (2%) were caused by anabolic androgenic steroids. Patients with herbal and dietary supplement‐induced liver injury were a mean age of 48 years and 63% were female; they presented a mean level of alanine aminotransferase 37‐fold the upper limit of normal, 28% had hypersensitivity features, and 78% had jaundice. Herbal and dietary supplement‐induced liver injury progressed to acute liver failure in 6% of patients, compared with none of the cases of anabolic androgenic steroid‐induced injury and 4% of cases of conventional drugs. Liver injury after repeat exposure to the same product that caused the first DILI episode occurred in 9% of patients with herbal and dietary supplement‐induced liver injury vs none of the patients with anabolic androgenic steroid‐induced injury and 6% of patients with liver injury from conventional drugs. Conclusion In an analysis of cases of herbal and dietary supplement‐induced liver injury in Spain, we found cases to be more frequent among young women than older patients or men, and to associate with hepatocellular injury and high levels of transaminases. Herbal and dietary supplement‐induced liver injury is more severe than other types of DILI and re‐exposure is more likely. Increasing awareness of the hepatoxic effects of herbal and dietary supplements could help physicians make earlier diagnoses and reduce the risk of serious liver damage.


Journal of Hepatology | 2015

P1097 : Distinguishing drug induced autoimmune hepatitis from idiopatic autoimmune hepatitis

A. Ortega-Alonso; A. Castiella; M. Robles-Díaz; I. Medina-Cáliz; Camilla Stephens; J. Sanabria; A. González-Jiménez; B. García-Muñoz; Miren García-Cortés; Eva Zapata; P. Otazua; S. Blanco; Martín Prieto; Fernando Bessone; Manuel Castro Fernández; H. Hallal; J. Primo; J.M. Moreno-Planas; Marco Arrese; R.J. Andrade; M.I. Lucena

M30/CK18-cleavage staining, indicators of hepatocyte apoptosis. Indicators of oxidative stress, including the accumulation of 4-HNEprotein adducts and JNK phosphorylation, were also increased. In contrast, mice deficient in MLK3 were protected from ethanolinduced increases in plasma ALT/AST, pro-inflammatory cytokines and hepatic protein expression of RIP3. Ethanol-induced JNK phosphorylation and oxidative stress were also attenuated in MLK3deficient mice. However, MLK3-deficiency did not affect ethanolinduced steatosis or hepatocyte apoptosis. Conclusions: Taken together, these results suggest that MLK3 participates in the development of ethanol-induced oxidative stress, activation of JNK and induction of necroptotic programmed hepatocyte death. Pharmacological intervention of this pathway could be targeted as a potential therapeutic strategy to suppress necroptosis-induced inflammation and hepatocyte injury in patients with ALD.


Gastroenterology | 2005

Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period

Raúl J. Andrade; M. Isabel Lucena; M. Carmen Fernández; G. Pelaez; Ketevan Pachkoria; Elena García-Ruiz; B. García-Muñoz; Rocío González-Grande; Angeles Pizarro; José Antonio Durán; Manuel Coheña Jiménez; Luis Rodrigo; Manuel Romero-Gómez; J.M. Navarro; Ramon Planas; Joan Costa; Africa Borras; Aina Soler; Javier Salmerón; Rafael Martin-Vivaldi


World Journal of Gastroenterology | 2006

Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report.

M. Isabel Lucena; Raúl J. Andrade; Luis Vicioso; F Jesús González; Ketevan Pachkoria; B. García-Muñoz


Journal of Hepatology | 2018

DRESS cases included in the Spanish and Latin-American DILI registries: clinical phenotype and outcome

I. Medina-Cáliz; M. Almarza; C. Stephens; M. Robles-Díaz; J. Sanabria-Cabrera; A. González-Jiménez; Rocío Sanjuan-Jimenez; A. Ortega-Alonso; M.G. Cortes; B. García-Muñoz; M. Quiros-Cano; Flores Martín-Reyes; A. Cueto; M. Fernández; Pere Ginès; M.R. Gomez; Germán Soriano; Martín Prieto; Isabel Conde; F. Bessone; N. Hernandez; M. Arrese; M. Cabello; M.I. Lucena; Raúl J. Andrade


Journal of Hepatology | 2017

Clinical characteristics and outcomes of elderly included in the Spanish Drug-Induced Liver Injury (DILI) Registry

M. Slim; J. Sanabria; M. Robles-Díaz; I. Medina-Cáliz; A. González-Jiménez; A. Ortega; Miren García-Cortés; B. García-Muñoz; R. Sanjuán-Jiménez; Manuel Castro Fernández; A. Castiella; Eva Zapata; H. Hallal; E. Montane; Germán Soriano; Eva Román; J.M. Navarro; M. Jiménez; Martín Prieto; I. Conde; A. Aldea; Manuel Hernández-Guerra; J.M. Moreno; Manuel Romero-Gómez; E. Gomez-Dominguez; M.I. Lucena; R.J. Andrade


Clinical Therapeutics | 2017

Idiosyncratic Drug-Induced Liver Injury: A 20-Year Update of the Cases Enrolled By the Spanish Dili Registry

M. Slim; J. Sanabria; M. Robles-Díaz; I. Medina-Cáliz; R. Sanjuán-Jiménez; A. González-Jiménez; A. Ortega; Miren García-Cortés; B. García-Muñoz; Manuel Castro Fernández; A. Castiella; Eva Zapata; H. Hallal; I. Conde; Martín Prieto; E. Montane; R. María Morillas; Germán Soriano; Eva Román; J.M. Navarro; Manuel Coheña Jiménez; A. Aldea; Manuel Hernández-Guerra; Pere Ginès; S. Blanco; J.M. Moreno; Manuel Romero-Gómez; E. Gomez-Dominguez; Raúl J. Andrade; María Isabel Lucena


Journal of Hepatology | 2016

Hepatotoxicity Associated with Non-Steroidal Anti-Inflammatory Drugs. A Comparative Analysis among Ibuprofen, Diclofenac and Nimesulide fromthe Spanish and Latin-American Dili Registries

A. González-Jiménez; I. Medina-Cáliz; M. Robles-Díaz; M.E. Zoubek; P. Díaz-Jimenez; M. Cabello; A. Ortega-Alonso; Miren García-Cortés; B. García-Muñoz; Manuel Castro Fernández; M. Slim; Manuel Romero-Gómez; Fernando Bessone; Nelia Hernández; Marco Arrese; E. Montane; H. Hallal; J. Sanabria-Cabrera; R. Sanjuan-Jiménez; M.I. Lucena; R.J. Andrade

Collaboration


Dive into the B. García-Muñoz's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Martín Prieto

Instituto Politécnico Nacional

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge